Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
rated new Hold at Deutsche Bank. $33 price target. Stock already trades at a premium to its peers.
downgraded at Jefferies from Buy to Hold. Valuation call, based on a $47 price target.
downgraded at Citigroup from Hold to Sell. $31 price target. Fundamentals are deteriorating, which could lead to slower growth.
downgraded at Jefferies from Buy to Hold. $37 price target. Consensus analyst estimates appear too high, because of lofty expectations for enterprise demand.
downgraded at Goldman from Buy to Neutral. Valuation call, based on a $20 price target.
upgraded at Barclays. CCL upgraded to Overweight from Equal Weight. Favorable industry mix shift to Europe in 2011. Price target raised to $52 from $43.
upgraded at Collins Stewart from Hold to Buy. $43 price target. Market is too pessimistic about generic competition of Lidoderm.
downgraded at UBS from Buy to Neutral. $76 price target. Earnings are falling quicker than expected.
downgraded at FBR from Outperform to Market Perform. Checks with home-improvement suppliers suggests flatter sales trends.
initiated at Barclays with an Equal Weight rating and $70 price target. Potential to take leadership in the left ventricular device market.
upgraded at JP Morgan to Overweight. $9 price target.
Leggett & Platt
downgraded at Stifel from Buy to Hold. Valuation call, until end-market demand improves.
downgraded at JP Morgan to Neutral. Valuation call, based on a $15.50 price target.
downgraded at JP Morgan from Overweight to Neutral. Valuation call, based on a $12 price target.
downgraded at FBR from Outperform to Market Perform. $27 price target. Enterprise PC refresh cycle may be slower than expected.
upgraded at Goldman to Buy. Fewer companies are suspending 401(k) matches. Company also likely to buy back stock next year.
downgraded at Oppenheimer from Outperform to Perform. $22 price target. Project delays could materialize, as backlog conversion lengthens.
upgraded at Barclays to Overweight from Equal Weight. Favorable industry mix shift to Europe in 2011. Price target boosted to $46 from $36.
rated new Buy at Goldman Sachs. $65 price target. Containerboard and boxboard prices should be sustainably higher through 2012.
upgraded at Citigroup from Hold to Buy. $5.50 price target. Expect that forward capacity prices will move higher.
United Natural Foods
downgraded at Canaccord from Buy to Hold. $38 price target. Company faces integration risk over the coming quarters.
downgraded at Credit Suisse to Neutral from Outperform on weaker earnings power in the near term. Price target raised by a dollar to $20.
rated new Buy at Deutsche Bank. $32 price target. Stock is pricing in near-term risks, and the programmable logic market offers a compelling opportunity.
STOCK COMMENTS / EPS CHANGES
estimates, target raised at Citigroup. Shares of ALB now seen reaching $57. Estimates also increased, given better pricing power. Buy rating.
Brown & Brown
numbers boosted at Citigroup. Shares of BRO now seen reaching $26. Estimates also upped, as margins are expanding. Buy rating.
estimates, target reduced at Goldman. Shares of BUCY now seen reaching $83. Estimates also lowered, because of lower near-term orders. Buy rating.
added to Conviction Buy List at Goldman. Valuation call, as the government sale should be done by mid-2011. $5.50 price target.
estimates, target increased at UBS. COH estimates were raised through 2012. Company is seeing better domestic sales. Neutral rating and $45 price target.
target, estimates cut at Credit Suisse. CYT price target lowered to $62 from $65. Communication issues caused stock drop, risk/reward profile attractive going forward. Estimates reduced through 2012. Maintain Outperform rating.
estimates, target lowered at Citigroup. Shares of CYT now seen reaching $57. Estimates also reduced, because of higher input costs. Hold rating.
target upped at Morgan Stanley to $46. Company has strong cost controls and should benefit from an advertising recovery. Equal-weight rating.
estimates, target boosted at Goldman. Shares of DOV now seen reaching $65. Estimates also upped, to match the company's new guidance. Buy rating.
price target raised at Barclays to $50 from $40. Expect underlying operating strength and aggressive buyback to continue. Maintain Overweight rating.
estimates lowered at Oppenheimer through 2011. Company is seeing lower enrollment rates. Perform rating.
estimates increased at UBS through 2011. Company is executing well in a difficult environment. Neutral rating and $41 price target.
estimates lowered at Jefferies. FE estimates were cut through 2012. Company will be hurt by lower auction results in Ohio. Underperform rating and $31 price target.
estimates changed at Credit Suisse. FE 2010 EPS estimate raised to $3.69, 2011 trimmed to $3.20. Sell-off overdone, recovery value remains. Maintain Outperform rating.
numbers raised at Jefferies. Shares of FFIV now seen reaching $115. Estimates also increased, as the company is seeing better spending on data center projects. Buy rating.
Fifth Third Bancorp
estimates increased at Morgan Stanley through 2012. Company is cleaning up its balance sheet, which improves the credit outlook. Equal-weight rating and $15 price target.
estimate cut at Barclays. FLR 2010 EPS estimate sunk to $2.30, 2011 held at $3.40. Pipeline improving despite 3Q choppiness. Maintain Overweight rating and $61 price target.
price target raised at Barclays to $75 from $69 following Friday's positive investor meeting. Maintain Equal Weight rating.
target boosted at Morgan Stanley to $95. Company has strong earnings momentum. Overweight rating.
price target increased at Credit Suisse to $50 from $45. Performance and position warrant multiple appreciation. Maintain Outperform rating.
numbers raised at UBS. Shares of HANS now seen reaching $57. Estimates also increased, as Monster should sustain its growth through 2011. Buy rating.
estimates, target raised at UBS. Shares of HON now seen reaching $49. Estimates also increased, to match the company's new guidance. Neutral rating.
price target higher at Barclays. IR price target lifted to $43 from $37 on solid 3Q beat. Maintain Equal Weight rating.
numbers increased at Goldman through 2012. Company is seeing better currency trends, in addition to lower corporate and interest costs. Neutral rating and new $44 price target.
numbers raised at Goldman. Shares of JNY now seen reaching $20. Estimates also increased, given higher expected gross margin at Weitzman. Neutral rating.
estimates, target increased at Oppenheimer. MCK estimates were raised through 2012. Company should benefit from recent strong generic launches. Outperform rating and new $78 price target.
estimates increased at Morgan Stanley through 2012. Company is realizing higher margins. Equal-weight rating.
estimates lowered at Goldman through 2012. Company is seeing lower margins on new vehicles. Neutral rating and $15 price target.
estimates, target raised at Citigroup. Shares of PNC now seen reaching $65. Estimates also increased, because of an improving credit outlook. Hold rating.
estimates upped at Morgan Stanley through 2012. Pall Mall and Camel are taking market share. Underweight rating.
price target boosted at Credit Suisse to $83 from $78. Encouraged by the breadth of earnings growth levers that can emerge forcefully by 2012. Maintain Outperform rating.
estimates upped at UBS through 2011. Offshore exploration should pick up and boost North American margins. Buy rating and $86 price target.
estimates, target raised at Morgan Stanley. Shares of STI now seen reaching $30. Estimates also increased, because of higher fees and net-interest income. Equal-weight rating.
estimates, target raised at Deutsche. Shares of T now seen reaching $33. Estimates also increased, as the company is generating solid core earnings growth. Buy rating.
T. Rowe Price
target raised at Credit Suisse. TROW price target boosted to $65 from $60. Institutional flows accelerate; new SEC rules could hurt large money market managers. Maintain Outperform rating.
estimates, target boosted at Citigroup. Shares of TRV now seen reaching $59. Estimates also upped, to match the company's new guidance. Hold rating.
numbers lowered at Deutsche Bank. Shares of URBN now seen reaching $35. Estimates also cut, as consumer spending remains choppy. Buy rating.
estimates, target upped at Goldman. VZ estimates were boosted through 2012. Company is generating better cash flow, because of wireless momentum. Tax rate is also lower than expected. Neutral rating and new $34 price target.
This article was written by a staff member of TheStreet.